Fortress Biotech的动态

"Compared to our peers and their technology, I feel CytoMed stock (NASDAQ:GDTC) is under-appreciated. And since we operate out of Asia, we may be relatively unknown in the US, for now, that is." - Peter Choo, Chairman CytoMed Therapeutics Limited #CarTcells #cartcelltherapy #cancertherapy #biotechstocks #biotech #undervalued #immunotherapy #nasdaq #nasdaqstocks #preclinical #undervaluedstocks #investing

Cynata Therapeutics Cynata’s Phase 1 trial results offer significant insights for investors, balancing potential risks with market opportunities. Read More https://lnkd.in/gE3E3dpJ #CynataTherapeutics, #CYP006TK, #investmentImplications, #biotechnologyRisks, #marketOpportunities

I'm excited to share an inspiring case study from Nimbus Therapeutics, showcasing the incredible work of Alex Benzell and Rebecca Carazza. They developed a series of Spotfire dashboards to manage their CRO projects, achieving remarkable results: ?? Reduced CRO data upload time ?? Minimized manual intervention ?? Streamlined projects Their innovative approach has significantly accelerated innovation. Kudos to Alex and Rebecca for their outstanding innovation! https://bit.ly/4a4SFYG #Revvity Signals

???????????????: 2 Discounted Passes Left for the ?????? ????????????????????-???????????????? ?????????????????? ????????????! ? Time is running out to be part of the ???????? ?????????????? ?????????? ???? ???????????????????? ????????????????????????. Don't risk falling behind as top experts ???????????????? ?????? ???????? ???????????????? ???????????????????? and share their ?????????????? ???? ?????????????????????? ?????? ?????????????????? ????????????????????????. ? ???????? ?????? ???????? ?????????????? - https://ter.li/ntamqp ? Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field. ? ? ???????? $?????? ???? ???????????????? ???????????????? - https://ter.li/ook4wg ? Don't let this opportunity slip away! ? #MacrophageDirectedTherapiesSummit

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

Hear from four biotech CMOs on the skills they needed to learn and how they adjusted as first-time CMOs. They address: ? How different backgrounds prepared them for the CMO role ? Where they needed to change how they worked ? How they found out what they didn’t know and how they learned those areas ? What they would have done differently Moderated by Dr Marcella Ruddy, Tectonic Therapeutic, Inc., panelists include: ? Dr Norman Sussman, DURECT Corporation ? Dr Mark Bach, GentiBio ? Dr Jeremy Sokolove, Odyssey Therapeutics ??? Watch the video here: https://lnkd.in/ehwkvGzB #CMOSummit360° #CMO #ChiefMedicalOfficer

Following a truly insight-rich discussion last week with Nicola McCarthy and Namshik Han of the Milner Therapeutics Institute and Biorelate's CSO Ben Sidders, you can now access the recorded webinar >> https://lnkd.in/eZsq-25A #drugdiscovery #artificialintelligence #bioinformatics

Building causal hypotheses in drug discovery ???? If you missed last week's panel discussion with our own Nicola McCarthy and Namshik Han, and Biorelate's Ben Sidders and Daniel Jamieson, you can now view the recording online! Where are the opportunities to use AI and data driven approaches to create more robust models for developing actionable hypotheses? How can biopharma make better use of data for developing mechanistic rationales that will improve drug discovery outcomes for drug developers and patients? Join the discussion by clicking here ?? https://lnkd.in/eZsq-25A

Solvonis Therapeutics CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's rebranding from Graft Polymer (UK) PLC (LSE:GPL) to Solvonis Therapeutics PLC, reflecting its commitment to advancing mental health and substance use disorder treatments. Tennyson highlighted Solvonis' plans to acquire Awakn Life Sciences in an all-stock deal, emphasising Awakn’s promising data, experienced team, and valuation. Watch at #Proactive #ProactiveInvestors https://lnkd.in/di-ctW-n